I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY) Tecentriq (atezolizumab) in patients with advanced cancer.
An abstract detailing data from the trial will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place next month.
I-Mab touted a 23% objective response rate and disease control rate of 46% in the study among 13 evaluable patients with several different types of advanced cancers.
A patient with ovarian cancer achieved a complete response; two others saw a partial response, while three had stable disease.
In particular, investigators reported no “hook effect” in the Phase I trial, meaning the antibody potency seemed to increase proportionately with the dose rather than losing inhibition at a higher dose, an issue observed with certain other drugs in the class.
The clinical activity was observed in both PD-(L)1 treatment naïve and refractory cancer patients, including one partial response patient who previously failed Bristol-Myers Squibb Co’s (NYSE: BMY) Opdivo (nivolumab).
The combination was safe and well-tolerated with no dose-limiting toxicity. All treatment-related adverse events were either mild or moderate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.